OUR SCIENCE
Shifting the cancer treatment paradigm

IMAGINE CANCER TREATMENT WITHOUT THE HARMFUL SIDE EFFECTS: THAT’S ADC TECHNOLOGY.

Physicians and scientists alike are characterizing antibody-drug conjugates (ADCs) as the next generation of cancer treatments. However, for an ADC therapeutic to be successful, many complex factors must work together in unison.

In order to combat tumor cells without affecting healthy tissue, ADCs are engineered to target cancer-specific proteins. Choosing the correct target protein is paramount. Currently, most known cancer proteins are either too broadly expressed or too specific to a given cancer subtype to be effective targets. At the same time, many antibodies are not specific enough to accurately target a cancer-specific protein. These issues are major obstacles in the current cancer treatment landscape.

1

For an ADC to be effective and safe, tumor cells alone should be targeted. When an ADC binds to healthy tissues, unwanted tissue damage, adverse events, and subsequently poor patient treatment adherence will occur due to these toxicities. At Stromatis Pharma, we create antibodies that are extensively validated for target binding specificity, ensuring that no off-target binding occurs.

2

Our lead assets target the CEACAM-family of proteins, which are preferentially expressed in cancer cells. The specificity of our antibodies is due to a unique epitope exclusive to CEACAM receptors.

3

By utilizing a propriety platform and antibody-generation strategies, including the virtual lymph node and DIADD technologies, we can dramatically improve antigen sensitivity and activate a more focused immune response. The resulting antibodies are superior, as specificity is increased markedly during the process.

4

Our current portfolio of antibodies binds to unique epitopes that are highly specific to tumor tissue.

5

The ADC binds to the CEACAM receptor on the cancer cell, initiating the process of internalization.

6

As the ADC complex traffics through the endolysosomal compartment, it is degraded via a pH-dependent mechanism allowing the payload to freely enter into the cytoplasm to induce cell death. Leveraging our expertise in ADC linker chemistry, we can modify the timing of payload release to optimize this process.

7

The precision of tumor cell death is made possible through our platform’s superior antibodies that target antigens frequently expressed in recalcitrant epithelial cancers, such as breast, lung, pancreatic, colorectal, ovarian, cervical, prostate, gastric, and urothelial cancers.

1

For an ADC to be effective and safe, tumor cells alone should be targeted. When an ADC binds to healthy tissues, unwanted tissue damage, adverse events, and subsequently poor patient treatment adherence will occur due to these toxicities. At Stromatis Pharma, we create antibodies that are extensively validated for target binding specificity, ensuring that no off-target binding occurs.

2

Our lead assets target the CEACAM-family of proteins, which are preferentially expressed in cancer cells. The specificity of our antibodies is due to a unique epitope exclusive to CEACAM receptors.

3

By utilizing a propriety platform and antibody-generation strategies, including the virtual lymph node and DIADD technologies, we can dramatically improve antigen sensitivity and activate a more focused immune response. The resulting antibodies are superior, as specificity is increased markedly during the process.

4

Our current portfolio of antibodies binds to unique epitopes that are highly specific to tumor tissue.

5

The ADC binds to the CEACAM receptor on the cancer cell, initiating the process of internalization.

6

As the ADC complex traffics through the endolysosomal compartment, it is degraded via a pH-dependent mechanism allowing the payload to freely enter into the cytoplasm to induce cell death. Leveraging our expertise in ADC linker chemistry, we can modify the timing of payload release to optimize this process.

7

The precision of tumor cell death is made possible through our platform’s superior antibodies that target antigens frequently expressed in recalcitrant epithelial cancers, such as breast, lung, pancreatic, colorectal, ovarian, cervical, prostate, gastric, and urothelial cancers.
Our Scientific Approach
Colorectal
Cervical
Lung
Pancreatic
Gastric

CEACAM5/6 receptors present a rare opportunity to target difficult-to-treat cancers: they occur in a wide variety of cancers, including colorectal, cervical, colon, non-small cell lung, and pancreatic, but are virtually undetectable in normal tissue. The unique specificity of our target in combination with our superior antibodies enables us to create advanced therapeutics for these cancers with few targeted treatment options. Our lead antibody, CT109, binds exclusively to CEACAM5/6, enabling the selective targeting of a wide range of epithelial cancers.

Join Stromatis Pharma in changing the cancer treatment paradigm

Contact us